© PR Newswire
09.12.2025
LNAI
LISTED
NASDAQ
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market
News Preview
SACRAMENTO, Calif., Dec. 9, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets that may accelerate proof-of-concept programs, derisk therapeutic developmen...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
JNJ
LISTED
NYSE
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
News Preview
TECVAYLI® and DARZALEX FASPRO® combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-upCombination regimen granted Breakthrough Therapy Designation by U.S. FDAORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
ELAN
LISTED
NYSE
Elanco Investor Day Defines New Era as Sustainable Growth Company
News Preview
Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to <3x in 2027, with a long-term target o...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
09.12.2025
CLTX
LISTED
NASDAQ
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
News Preview
Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates ...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
09.12.2025
OSTX
LISTED
XASE
OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
News Preview
Alignment achieved on all key points surrounding non-clinical, CMC and post-market authorization confirmatory study designBiomarker data advanced as key pre-specified surrogate clinical efficacy endpoint, with pending analysis awaiting alignment with US FDA on biomarker statistical analysis plan to be discussed at upcoming December 11, 2025 FDA Typ...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
LLY
LISTED
NYSE
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
News Preview
The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal of Clinical Oncology and highlighted in a late-breaking oral presentation at the 2025 American Society of Hematology Annual Meeting and Exposition,...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
APRE
LISTED
NASDAQ
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
News Preview
Financing from new and existing healthcare focused investors...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
ICLR
LISTED
NASDAQ
ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive
News Preview
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
MBRX
LISTED
NASDAQ
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
News Preview
Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range...
Themefolio
Profiler
Peergroup
© EQS Newswire
09.12.2025
FYB
LISTED
XETR
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
News Preview
Presse Release // December 09, 2025
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful lau......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.12.2025
FYB
LISTED
XETR
Formycon und Zydus schließen exklusive Lizenz- und Liefervereinbarung für FYB206, ein Biosimilar für Keytruda® (Pembrolizumab), in den USA und Kanada
News Preview
Pressemitteilung // 09. Dezember 2025
Formycon und Zydus schließen exklusive Lizenz- und Liefervereinbarung für FYB206, ein Biosimilar für Keytruda® (Pembrolizumab), in den USA und Kanada
Lizenzpartner Zydus verfügt über umfangreiche kommerzielle Erfahrung und vermarktet mehr als 225 von der FDA zugelassene Medikamente – eine starke Ausgangsbasi......
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
CLDX
LISTED
NASDAQ
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
News Preview
HAMPTON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the initiation of its global Phase 3 trial (EMBARQ-ColdU and SD) designed to establish the efficacy and safety of barzolvolimab in adult patients with cold urticaria (ColdU) and symptomatic dermographism (SD) who remain symptomatic despite H1 antihistamine trea...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
09.12.2025
CYPH
LISTED
NASDAQ
Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor
News Preview
CAMBRIDGE, Mass., Dec. 9, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that industry pioneer Zooko Wilcox, the founder of Zcash, former CEO of the Electric Coin Company, and current Chief Product Officer of Shielded Labs, has joined the company as a Strategic Advisor.
Zooko brings a decades-long track record of...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
CYPH
LISTED
NASDAQ
Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor
News Preview
CAMBRIDGE, Mass., Dec. 9, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that industry pioneer Zooko Wilcox, the founder of Zcash, former CEO of the Electric Coin Company, and current Chief Product Officer of Shielded Labs, has joined the company as a Strategic Advisor.
Zooko brings a decades-long track record of...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
CYPH
LISTED
NASDAQ
Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor
News Preview
CAMBRIDGE, Mass., Dec. 9, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that industry pioneer Zooko Wilcox, the founder of Zcash, former CEO of the Electric Coin Company, and current Chief Product Officer of Shielded Labs, has joined the company as a Strategic Advisor.Zooko brings a decades-long track record of s...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
GRIN
LISTED
CSE
Grown Rogue Secures Cultivation Facility in Minnesota
News Preview
Location Approved for Cannabis Cultivation; Construction Planned in 2026 with First Product Anticipated in Early 2027MEDFORD, Ore., Dec. 9, 2025 /CNW/ - Grown Rogue International Inc. ("Grown Rogue" or the "Company") (CSE: GRIN) (OTC: GRUSF), a flower-forward cannabis company combining craft values with disciplined execution, today announced that...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
CYPH
LISTED
NASDAQ
Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor
News Preview
CAMBRIDGE, Mass., Dec. 9, 2025 /CNW/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that industry pioneer Zooko Wilcox, the founder of Zcash, former CEO of the Electric Coin Company, and current Chief Product Officer of Shielded Labs, has joined the company as a Strategic Advisor.Zooko brings a decades-long track record of shaping...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
CBLL
LISTED
NASDAQ
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
News Preview
Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
LBRX
LISTED
NASDAQ
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
News Preview
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the Company has been included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets on December 22, 2025, as part of the 2025 Russell indexes reconsti...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
IPSC
LISTED
NASDAQ
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
News Preview
PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. As...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
TEVA
LISTED
TLV
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
News Preview
PARSIPPANY, N.J. and TEL AVIV, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for olanzapine extended-release injectable suspension (TEV-'749)...
Themefolio
Profiler
Peergroup
© Newsfile
09.12.2025
MUSL
LISTED
CSE
Promino Announces Secured Convertible Debenture Offering for Proceeds of up to $1 Million
News Preview
Burlington, Ontario--(Newsfile Corp. - December 9, 2025) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company") announces it intends to complete a non-brokered private placement of secured convertible debentures (the "Convertible Debentures") of the Company for an aggregate principal amount of up to $1...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
PLSE
LISTED
NASDAQ
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology
News Preview
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced a research collaboration with The University of Texas MD Anderson Cancer Center to examine the use of the Company...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
PEPG
LISTED
NASDAQ
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
XNCR
LISTED
NASDAQ
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
News Preview
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S. Patent 12,492,253, which covers Xencor’s Xtend™ Fc domain for extending the half-life of antibodies targeting C5, with a term that extends into December 20...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
45680
LISTED
XJPX
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
News Preview
The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy in patients with HER2 expressing (IHC 3+/2+/1+) advanced high-grade epithelial ovarian cancer following trea...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
2196
LISTED
HKSE
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
News Preview
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Un...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
TECH
LISTED
NASDAQ
Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis
News Preview
Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexingEnables up to 24 targets per sample and supports complex assay configurationsStrengthens Bio-Techne's leadership in proteomic analytical instruments and supports 21 CFR Part 11 complianceMINNEAPOLIS, De...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
CVS
LISTED
NYSE
CVS Health Updates Financial Guidance, Highlights Strength of Businesses, and Announces Strategy to Uniquely Reimagine Health Care at Investor Day Event
News Preview
Outlines strategy to deliver best-in-class execution, transform consumer experiences, be the partner of choice, and harness unique enterprise capabilities Updates 2025 full-year financial guidance; provides 2026 full-year financial guidance Commits to mid-teens Adjusted EPS CAGR through 2028 Announces strategy to uniquely reimagine health care thr...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
CRON
LISTED
TSX
Cronos to enter the Netherlands with acquisition of Europe’s largest adult-use cannabis company
News Preview
Cronos to acquire CanAdelaar for up-front cash consideration of US$67.0M1 plus cash earnout of 0.5x normalized EBITDA in 2026 and 2027...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
BCT
LISTED
TSX
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
News Preview
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 clinical study has screened over 230 and en...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
PFE
LISTED
NYSE
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
News Preview
Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002,...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
FYB
LISTED
XETR
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
News Preview
PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today jointly announced that they have entered into a strategic partnership for the exclusive licensing and supply of checkpoint inhibitor FYB2...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
IRD
LISTED
NASDAQ
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
News Preview
Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trial Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trial...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
FRX
LISTED
TSX
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
News Preview
– City of Hope to Evaluate PEDMARK® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors –...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
CSTL
LISTED
NASDAQ
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
News Preview
Castle Biosciences announced the publication of an independent expert consensus paper endorsing the Company’s DecisionDx-Melanoma test....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
TNXP
LISTED
NASDAQ
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
News Preview
Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
LGND
LISTED
NASDAQ
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
News Preview
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Monthly Fact Sheet as at 30 November 2025
News Preview
Worldwide Healthcare Trust PLC
(the "Company")
9 December 2025
LEI: 5493003YBCY4W1IMJU04
Monthly Fact Shee...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
TERN
LISTED
NASDAQ
Terns Announces Proposed Public Offering
News Preview
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded w...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.12.2025
MDCE
LISTED
OTC
Medical Care Technologies Inc. (OTC Pink:MDCE) Sees Significant Surge in Investor Activity as Share Structure Stabilizes and New Tech Partnership Forms
News Preview
MESA, ARIZONA / ACCESS Newswire / December 9, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) is pleased to announce a marked rise in trading activity and shareholder engagement as the Company transitions into a new phase of technology-driven growth and leaves behind dilution tied to its previous Regulation A offering. Over recent trading se...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.12.2025
IGC
LISTED
XASE
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
News Preview
POTOMAC, MARYLAND / ACCESS Newswire / December 9, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced it has reached a key enrollment milestone of 65% for its...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.12.2025
PTIX
LISTED
NASDAQ
Results from Phase 1 Multiple-Dose Study of PT00114
News Preview
Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing therapeutics that target the biology of chronic stress and its downstream...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.12.2025
APVO
LISTED
NASDAQ
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
News Preview
100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care SEATTLE, WA / ACCESS Newswire / December 9, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.12.2025
AIML
LISTED
CSE
AIML subsidiary NeuralCloud Solutions Signs Commercial Term Sheet with Culminate H Labs to Deploy MaxYield(TM) and Insight360(TM) into INTRINSICA's DNA-Guided Biofeedback Wellness Ecosystem
News Preview
This strengthens NeuralCloud's expansion into the global wellness and B2B health practitioner delivery model with high-fidelity cardiac signal processing and digital health integration.Partnership positions MaxYield™ as a core AI engine for next-generation smart rings and consumer cardiac monitoring into the broader INTRINSICA platform. TORON...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
News Preview
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
ROG
LISTED
SIX
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
News Preview
Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and yeast responsible for BV and CV in vaginal samples from symptomatic patients collected using the cobas PCR Media proprietary tube....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
ROG
LISTED
SIX
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
News Preview
Basel, 9 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyva®/Gazyvaro® (obinutuzumab) in combination with mycophenolate mofetil (MMF) for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis. These disease classifications de...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
09.12.2025
XPHY
LISTED
CSE
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
News Preview
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your Mouth" cladribine formulation, built on the Company's proprietary oral dissolvable film (ODF) drug-delivery system. The...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
9926
LISTED
HKSE
Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia
News Preview
HONG KONG, Dec. 8, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that at the 2025 ESMO Asia Congress, updated results from the pivotal Phase III HARMONi-6 study (AK112-306) were shared in an oral presentation by Professor Shun Lu from Shanghai Chest Hospital. The study evaluates ivonescimab (a first-in-class PD-1/...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
ALGN
LISTED
NASDAQ
Align Technology Announces Invisalign® System With Mandibular Advancement Featuring Occlusal Blocks for Class II Skeletal and Dental Correction
News Preview
Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced commercial availability in Thailand of the Invisalign System with...
Themefolio
Profiler
Peergroup
© Newsfile
09.12.2025
SOL
LISTED
CSE
SOL Global Announces Share Consolidation
News Preview
Toronto, Ontario--(Newsfile Corp. - December 8, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL" or the "Company") announces that a majority vote by its Board of Directors has resolved to complete a share consolidation (the "Consolidation") of its issued and outstanding common shares (each, a "Pre-Consolida...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
9969
LISTED
HKSE
Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
News Preview
The study of mesutoclax in the treatment of r/r MCL was selected for oral presentation, while the CLL/SLL and AML studies were chosen for poster....
Themefolio
Profiler
Peergroup
© Newsfile
09.12.2025
DOSE
LISTED
CSE
Rapid Dose Completes Extension to Promissory Notes
News Preview
Burlington, Ontario--(Newsfile Corp. - December 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that it has extended the maturity date of its outstanding secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing") which closed in 2023. The Not...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
1801
LISTED
HKSE
Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
News Preview
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
6855
LISTED
HKSE
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
News Preview
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced tha...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
6855
LISTED
HKSE
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
News Preview
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced th...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2025
6855
LISTED
HKSE
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
News Preview
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced th...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
BIOA B
LISTED
STO
Leqembi included in China's commercial insurance innovative drug list
News Preview
STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of Leqembi in this list marks a...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2025
BIOA B
LISTED
STO
Leqembi included in China's commercial insurance innovative drug list
News Preview
STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of Leqembi in this list marks a...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
